OnKure is working closely with Dr. Gail Eckhart’s laboratories at the University of Texas-Austin, Dell medical School. The collaboration is focused on translating our research into tools and treatments to improve patient health outcomes, with a focus on precision medicine that personalizes cancer treatments based on the latest developments in molecular diagnostics. Dr. Eckhardt’s translational research team is focused on identifying rational combinations of targeted therapies that include epigenetic primers with an emphasis on identifying useful biomarkers for patient stratification.
OnKure entered into a clinical trial collaboration and supply agreement with Pfizer Inc. (NYSE: PFE) to support the clinical proof of concept study for MEKTOVI® (binimetinib) in combination with OKI-179, for the treatment of patients with NRAS melanoma. Pursuant to the agreement, Pfizer will provide MEKTOVI for use in the study and OnKure will be responsible for the conduct, and the cost, of the study. OnKure and Pfizer will form a Joint Development Committee to review clinical trial results from the OnKure-sponsored study. The clinical combination trial is targeted to initiate in mid-2021.
KDAc Therapeutics, Inc.
OnKure entered into an exclusive license and option agreement with Massachusetts-based KDAc Therapeutics, Inc. to support the continued development of KDAc’s HDAC3 selective inhibitor program. KDAc Therapeutics is a biotechnology company founded on technologies licensed from the Broad Institute of MIT and Harvard to translate discoveries in lysine acetylation and epigenetic regulation into novel treatments for cancer patients.